研究業績

2026年

1. Sugitani I, Kiyota N, Imai H, Takahashi S, Nishiyama A, Tamura S, Shimizu Y, Kadowaki S, Ito K, Hirashima Y, Ueno S, Katayama T, Tahara M. Encorafenib plus binimetinib for BRAF V600-mutated thyroid cancer in Japan: final analysis. Int J Clin Oncol. 2026;31(10):2223-33.

2. Kano S, Taguchi J, Maeda T, Suzuki T, Hamada S, Kato S, Saito A, Shimizu Y, Homma A. Conversion surgery following trastuzumab and docetaxel combination therapy for unresectable HER2-positive parotid gland cancer. Auris Nasus Larynx. 2026;53(3):328-31.

3. Matsubara N, Saijo K, Shimizu Y, Okano S, Nakano K, Nishio N, Otsuka T, Kuno H, Miura T, Kubota T, Ikezawa H, Umetsu Y, Ito K, Apfel A, Ye Y, Honma Y. First-in-human study: dose expansion of E7130 in urothelial carcinoma and squamous cell carcinoma of the head and neck. Cancer Sci. 2026;117(8):2247-58. doi: 10.1111/cas.70420.

4. Kiyota N, Tahara M, Imai H, Takahashi S, Nishiyama A, Tamura S, Shimizu Y, Kadowaki S, Ito K, Hirashima Y, Ueno S, Sugitani I. Health-related quality of life with encorafenib plus binimetinib for BRAFV600E thyroid cancer. Eur Thyroid J. 2026;15(2):ETJ250273.

5. Tahara M, Kiyota N, Imai H, Takahashi S, Nishiyama A, Tamura S, Shimizu Y, Kadowaki S, Ito K, Hirashima Y, Ueno S, Sugitani I. A study to learn how well the combination of encorafenib and binimetinib works and how safe it is in adults with thyroid cancer: a plain language summary. Future Oncol. 2026;22(8). doi: 10.1080/14796694.2026.2635933.

6. Saito Y, Takekuma Y, Sakakibara-Konishi J, Shimizu Y, Kinoshita I, Sugawara M. Impact of baseline regular magnesium oxide administration on chemotherapy-induced constipation during cisplatin-containing treatment. Int J Clin Oncol. 2026;31(2):336-46.

7. Saito Y, Watanabe T, Takekuma Y, Sakakibara-Konishi J, Shimizu Y, Kinoshita I, Sugawara M. Evaluating the potential to predict chemotherapy-induced nausea and vomiting in carboplatin-containing treatment based on symptoms induced by prior cisplatin-containing treatment. Sci Rep. 2026;16(1):5817.

8. Okamoto K, Hijioka S, Kobayashi N, Imaoka H, Hara K, Takeuchi S, Fujimori N, Sudo K, Horiguchi S, Takada R, Ono T, Terashima T, Shioji K, Kondo S, Furukawa T, Ueno M, Tsumura H, Tobimatsu K, Doi T, Asama H, Kawaguchi S, Kitano Y, Maeda O, Kobayashi S, Arima S, Unno M, Ohno E, Kawata K, Ashida R, Naganuma A, Murohisa G, Yamada R, Satake H, Kodama Y, Yokota I, Okuyama H, Shimizu S, Morizane C, Ueno M, Nagano H, Furuse J; Japan Oncology Network in Hepatobiliary and Pancreas. Efficacy and safety of peptide receptor radionuclide therapy with 177Lu-DOTATATE in Japanese patients with advanced neuroendocrine neoplasm: a multicenter retrospective study (JON2203-N). J Gastroenterol. 2026;61(8):1159-69.

9. Niwa K, Takeuchi S, Tsuchikawa T, Nakamura T, Takeuchi S, Morita R, Abo D, Hirata K, Mitsuhashi T, Hirano S. Multidisciplinary surgical management with chemotherapy and transcatheter arterial embolization for a giant hypervascular pancreatic neuroendocrine tumor. Clin J Gastroenterol. 2026;19(1):63-70.

10. Kano S, Hamada S, Taguchi J, Tsushima N, Idogawa H, Imanari H, Kakumu M, Sakai M, Shimizu Y, Homma A. Histological heterogeneity of SLFN11 expression and its association with response to carboplatin plus paclitaxel therapy in salivary gland cancer. Int J Clin Oncol. 2026. doi: 10.1007/s10147-026-03183-z.

11. Inoue T, Kono M, Kumai T, Obata K, Kano S, Ohkoshi A, Kakiuchi A, Taguchi J, Tagawa A, Matsushita D, Miyaguchi J, Endo T, Ishii R, Ito K, Ishida E, Suzuki T, Araki N, Kawase T, Takano K, Takahara M. Objective response rate predicts survival in recurrent or metastatic head and neck squamous cell carcinoma treated with immune checkpoint blockade but not with targeted therapy: a retrospective multicenter study. Cancer. 2026;132(8):e70429.

12. Sato S, Imafuku K, Ariga S, Ujiie H. mTOR-Responsive PIK3CA p.E542K-Harboring Sweat Gland Carcinoma With Neuroendocrine Differentiation. Int J Dermatol. 2026;65(11):2424-6. doi: 10.1111/ijd.70556.

13. Kawamura MM, Matsuoka M, Ujiie H, Ariga S, Nakazato S, Kato K, Hashimoto T, Matsuno Y, Kato T, Iwasaki N. Cryptococcal Lung Infection Simulating Metastasis in a Myxoid Liposarcoma Patient: A Case Report. Case Rep Infect Dis. 2026;2026:5538208.

14. Yamashita S, Saito Y, Tamaki S, Hirate D, Wakai K, Yonezawa I, Hirasawa H, Kashiwagi H, Sato Y, Imai S, Nashimoto S, Sakakibara-Konishi J, Shimizu Y, Kinoshita I, Takagi R, Sugawara M, Takekuma Y. Risk factors of docetaxel-induced peripheral edema in non-small cell lung cancer treatment: a multi-institutional cohort study. Jpn J Clin Oncol. 2026;56(9):1088-96.

15. Saito Y, Taniguchi O, Takekuma Y, Sakakibara-Konishi J, Shimizu Y, Kinoshita I, Sugawara M. Factors Associated With Rash in Elderly Patients Receiving Carboplatin Plus Pemetrexed With Dexamethasone Prophylaxis. Anticancer Res. 2026;46(9):5249-58.

16. Saito Y, Takekuma Y, Sakakibara-Konishi J, Shimizu Y, Kinoshita I, Sugawara M. Identification of Factors Associated With Clinically Problematic Hiccups in Male Patients Receiving Cisplatin-based Treatment With Dexamethasone and Aprepitant: A Subgroup Analysis. In Vivo. 2026;40(5):3047-55.

17. Okuma HS, Tsuchihashi K, Baba E, Takahashi M, Kinoshita I, Muto M, Kamikura M, Sadachi R, Shibata T, Ichimura M, Sakamoto W, Hirata Y, Nakamura K, Yonemori K. Real-world characterization of patients with advanced or metastatic liposarcoma, including dedifferentiated liposarcoma, in Japan in the MASTER KEY project. Jpn J Clin Oncol. 2026;56(5):577-86.

18. Okuma HS, Arakawa A, Hirakawa A, Kohsaka S, Yamada T, Anjo K, Kurishita K, Nakamura K, Kohno T, Matsumoto S, Tsuchihashi K, Kinoshita I, Yonemori K, Goto Y. Efficacy and Safety of Alectinib in Pediatric and Adult Patients with ALK-Altered Advanced Solid Tumors: a phase II TACKLE Trial (NCCH1712/MK003). Clin Cancer Res. 2026. doi: 10.1158/1078-0432.CCR-26-1548.

19. Nofuji K, Mariya T, Kubo T, Murota A, Teramoto M, Habata S, Matsuura M, Iwasaki M, Ishikawa A, Takada K, Idogawa M, Kinoshita I, Sakurai A, Saito T. Earlier Comprehensive Cancer Genomic Profiling in Gynecologic Cancers May Facilitate Genotype-Matched Therapy: A Prospective Single-Institution Study. Obstet Gynecol Int. 2026;2026:9990671.

20. Kanai M, Sunami K, Shimoi T, Nishiwaki S, Kinoshita I, Yoshinami T, Morizane C, Sato Y, Kubo T, Ito M, Nishihara H, Mukohara T, Shirota H, Ko R, Shibata T, Muto M, Yamamoto N. Phase II Trial of Nivolumab in Advanced Solid Tumors Based on Genomic Profiling: BELIEVE Trial (NCCH1901) Subcohort. Cancer Sci. 2026;117(10):2819-26.

21. Arisato H, Noguchi T, Shiiya A, Toji Y, Kashima M, Taguchi J, Takeuchi S, Shimizu Y, Kitai H, Murakami K, Sakakibara-Konishi J, Kinoshita I, Murakami M, Dosaka-Akita H, Konno S. Immune checkpoint blockade facilitates primary tumor rejection in a cDC1-independent manner but fails to induce durable immunological memory. Cancer Immunol Immunother, in press.

2025年

1. Saito Y, Takekuma Y, Sakakibara-Konishi J, Shimizu Y, Kinoshita I, Sugawara M. Evaluation of factors associated with clinically problematic hiccups in cisplatin-containing treatment with dexamethasone and neurokinin 1 receptor antagonists. Int J Clin Oncol. 2025;30(12):2504-11.

2. Saito Y, Taniguchi O, Takekuma Y, Sakakibara-Konishi J, Shimizu Y, Kinoshita I, Sugawara M. Younger age as a risk factor for rash development in pemetrexed and carboplatin treatment with dexamethasone prophylaxis. Support Care Cancer. 2025;33(11):932.

3. Kano S, Kiyota N, Kinoshita I, Tada Y, Ijichi K, Yamazaki T, Shimizu Y, Hatanaka Y, Tsuda H, Morinaga S, Matsuno Y, Ito YM, Nishimoto N, Kobayashi K, Isoe T, Noguchi T, Homma A, Dosaka-Akita H. Multicenter phase II trial of trastuzumab and docetaxel for HER2-positive salivary gland cancer. Jpn J Clin Oncol. 2025;55(10):1131-40.

4. Boku S, Fujisawa T, Kadowaki S, Satake H, Yasui H, Ohtsubo K, Shimizu Y, Otsuka T, Kuze B, Yamashita R, Shibuki T, Nakamura Y, Bando H, Yoshino T, Radovich M, Okano S. Resistance mechanism to pembrolizumab in DEK-AFF2 fusion-associated sinonasal squamous cell carcinoma. Int Cancer Conf J. 2025;14(4):458-63.

5. Kano S, Suzuki T, Yoshida D, Tsushima N, Idogawa H, Katsumata R, Yasuda K, Kinota N, Yamasaki K, Shimizu Y, Taguchi J, Aoyama H, Homma A. Improved local control and survival outcomes with RADPLAT in T4 oropharyngeal cancer: a retrospective study. Int J Clin Oncol. 2025;30(6):1127-35.

6. Watanabe T, Oka H, Nagashima K, Nishi H, Kumai Y, Iijima H, Okami K, Shimizu Y, Kano S, Ito K, Yamazaki T, Takahashi H, Oridate N, Yokota T, Koyama T, Kiyota N, Sato Y, Takahashi S, Kato K, Kadowaki S, Honma Y. Clinical outcomes of recurrent or metastatic head and neck cancer after failure of platinum and nivolumab: a multicenter retrospective study. Oncologist. 2025;30(3):oyaf018.

7. Noguchi T, Ariga S, Moku R, Kikuchi J, Amano T, Maeda T, Ishikawa K, Maeda T, Shiiya A, Goda T, Ohhara Y, Hagio K, Saito Y, Hatanaka KC, Hatanaka Y, Taguchi J, Takeuchi S, Shimizu Y, Kinoshita I. Actionable Gene Alterations Identified in Patients With Malignant Melanoma by Targeted Sequencing in Japan. JCO Precis Oncol. 2025;9:e2400437.

8. Wakabayashi N, Watanabe S, Takeuchi S, Tsuchikawa T, Munakata Y, Hirata K, Kimura R, Takenaka J, Ishii H, Kudo K. Factors and predictors affecting late external dose rates and isolation period in patients after lutetium-177-labeled DOTA-Tyr3-octreotate treatment for neuroendocrine tumors. Ann Nucl Med. 2025;39(7):696-706.

9. Takenaka J, Watanabe S, Abe T, Takeuchi S, Hirata K, Kimura R, Ishii H, Wakabayashi N, Majigsuren M, Kudo K. The biochemical-imaging connection: urinary noradrenaline and fluorodeoxyglucose-positron emission tomography in unresectable or metastatic pheochromocytomas and paragangliomas. Diagnostics (Basel). 2025;15(11):1305.

10. Kase S, Yamashita Y, Takeuchi S, Ishida S. Case report: laser speckle flowgraphy in a patient with uveitis due to immune-related adverse events by immune checkpoint inhibitors. Front Oncol. 2025;15:1492011.

11. Takenaka J, Watanabe S, Abe T, Takeuchi S, Hirata K, Kimura R, Ishii H, Wakabayashi N, Majigsuren M, Kudo K. Urinary dopamine levels can predict the avidity of post-therapy [131I]MIBG scintigraphy in unresectable or metastatic pheochromocytomas and paragangliomas: a preliminary clinical study. Pharmaceuticals (Basel). 2025;18(2):165.

12. Obata K, Kano S, Ohkoshi A, Kakiuchi A, Inoue T, Taguchi J, Tagawa A, Matsushita D, Miyaguchi J, Endo T, Ishii R, Ito K, Ishida E, Suzuki T, Araki N, Kawase T, Takano K. Prognostic factors and overall survival for recurrent and metastatic head and neck squamous cell carcinoma: a multicenter retrospective analysis. Jpn J Clin Oncol. 2025;55(9):1013-21.

13. Tanabe H, Ando K, Takahashi K, Kamanaka T, Yuzawa S, Kikuchi J, Ohhara Y, Ariga S, Shonaka T, Tani C, Otake S, Sasaki T, Takahashi K, Ueno N, Moriichi K, Tanino M, Kinoshita I, Mizukami Y, Fujiya M. Clinical utility of comprehensive genomic profiling test for colorectal cancer: a single institution prospective observational study. J Cancer Res Clin Oncol. 2025;151(9):253.

14. Ono M, Takahashi I, Kudo T, Miyazaki N, Azuma T, Horinouchi H, Kinoshita I, Nakajima TE, Yoshino T, Minami H. Barriers to career development and gender-related challenges in oncology: the results of the JSMO and JSCO surveys in Japan. ESMO Real World Data and Digital Oncology. 2025;10:100186. doi: 10.1016/j.esmorw.2025.100186.

15. Okagawa Y, Kubo T, Ariga S, Suzuki N, Tanabe H, Sogabe S, Ishiguro A, Ikeda T, Minami S, Hirakawa M, Kinoshita I, Takada K. Characterization of the mutational landscapes in Japanese patients with early-onset colorectal cancer from comprehensive genomic profiling data. Int J Clin Oncol. 2025;30(12):2596-604.

16. Kano S, Kinoshita I, Dosaka-Akita H. Author's reply to "Multicenter phase II trial of trastuzumab and docetaxel for HER2-positive salivary gland cancer". Jpn J Clin Oncol. 2025;55(11):1298.

2024年

1. Saito Y, Taniguchi O, Takekuma Y, Sakakibara-Konishi J, Shimizu Y, Kinoshita I, Sugawara M. Impact of baseline renal impairment on severe neutropenia development in pemetrexed and carboplatin thoracic cancer treatment. Support Care Cancer. 2024;32(12):829.

2. Saito Y, Takekuma Y, Sakakibara-Konishi J, Shimizu Y, Kinoshita I, Sugawara M. Effect of baseline anemia on the efficacy of docetaxel and ramucirumab for advanced non-small cell lung cancer treatment. BMC Cancer. 2024;24(1):1301.

3. Oridate N, Takahashi S, Tanaka K, Shimizu Y, Fujimoto Y, Matsumoto K, Yokota T, Yamazaki T, Takahashi M, Ueda T, Hanai N, Yamaguchi H, Hara H, Yoshizaki T, Yasumatsu R, Nakayama M, Shiga K, Fujii T, Mitsugi K, Takahashi K, Nohata N, Gumuscu B, Lerman N, Tahara M. First-line pembrolizumab with or without chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up of the Japanese population of KEYNOTE-048. Int J Clin Oncol. 2024;29(12):1825-39.

4. Tsujikawa T, Ohno K, Morita K, Saburi S, Mitsuda J, Yoshimura K, Kimura A, Morimoto H, Ogi H, Shibata S, Akashi T, Kurata M, Imoto I, Shimizu Y, Kano S, Watanabe A, Yamazaki T, Asada Y, Hayashi R, Saito Y, Ozawa H, Tsukahara K, Oridate N, Sano D, Horii A, Ueki Y, Maruo T, Mukoyama N, Hanai N, Fukusumi T, Iwai H, Fujisawa T, Fujii T, Nibu KI, Iwae S, Ueda T, Chikuie N, Yasumatsu R, Matsuo M, Umeno H, Ono T, Masuda M, Toh S, Itoh K, Hirano S, Asakage T. Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma. Front Immunol. 2024;15:1390873.

5. Nakazono A, Motegi H, Suzuki M, Nakamaru Y, Yamaguchi S, Ishi Y, Kano S, Tsushima N, Honma A, Suzuki T, Kimura S, Hamada S, Taguchi J, Shimizu Y, Mori T, Yasuda K, Aoyama H, Kinoshita I, Fujimura M, Homma A. Clinical outcomes for olfactory neuroblastoma. Front Oncol. 2024;14:1329572.

6. Watanabe T, Saito Y, Takekuma Y, Shimizu Y, Kinoshita I, Komatsu Y, Sugawara M. Evaluation of the risk factors for the failure of a single prophylactic dose of anticholinergic drugs for irinotecan-induced cholinergic symptoms. Int J Clin Pharmacol Ther. 2024;62(5):213-21.

7. Uchinami Y, Yasuda K, Minatogawa H, Dekura Y, Nishikawa N, Kinoshita R, Nishioka K, Katoh N, Mori T, Otsuka M, Miyamoto N, Suzuki R, Kobashi K, Shimizu Y, Taguchi J, Tsushima N, Kano S, Homma A, Aoyama H. Impact of adaptive radiotherapy on survival in locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiotherapy. Radiat Oncol J. 2024;42(1):74-82.

8. Tahara M, Kiyota N, Imai H, Takahashi S, Nishiyama A, Tamura S, Shimizu Y, Kadowaki S, Ito K, Toyoshima M, Hirashima Y, Ueno S, Sugitani I. A phase 2 study of encorafenib in combination with binimetinib in patients with metastatic BRAF-mutated thyroid cancer in Japan. Thyroid. 2024;34(4):467-76.

9. Saito Y, Sakamoto T, Kobayashi M, Takekuma Y, Higuchi I, Okamoto K, Sakakibara-Konishi J, Shimizu Y, Kinoshita I, Sugawara M. Evaluation of Prediabetes in Cisplatin-induced Nephrotoxicity in the Short Hydration Method: A Subgroup Analysis. In Vivo. 2024;38(2):800-6.

10. Sakamoto T, Kado M, Saito Y, Uchiyama K, Kanno R, Taniguchi O, Takekuma Y, Sakakibara-Konishi J, Shimizu Y, Kinoshita I, Sugawara M. Evaluation of Efficacy of Adding Aprepitant to Palonosetron and Dexamethasone in Carboplatin and Etoposide Therapy. Biol Pharm Bull. 2024;47(6):1189-95.

11. Yasuda K, Uchinami Y, Kano S, Taguchi J, Kawakita D, Kitayama M, Nishioka K, Mori T, Koizumi F, Fujii Y, Shimizu Y, Kobashi K, Yoshimoto S, Nibu K, Homma A, Aoyama H. Radiotherapy with or without chemotherapy for locally advanced head and neck cancer in elderly patients: analysis of the Head and Neck Cancer Registry of Japan. Int J Clin Oncol. 2024;29(3):241-7.

12. Zhang H, Tsuchikawa T, Takeuchi S, Hirata K, Tanaka K, Matsui A, Nakanishi Y, Asano T, Noji T, Nakamura T, Takeuchi S, Wada M, Hirano S. Initial validation of the clinical significance of the NETest in Japanese gastroenteropancreatic neuroendocrine tumor patients. Endocr J. 2024;71(9):873-80.

13. Yamaguchi A, Saito Y, Okamoto K, Furugen A, Narumi K, Takekuma Y, Sakakibara-Konishi J, Shimizu Y, Kinoshita I, Sugawara M, Kobayashi M. Association Between Multisystem Immune-related Adverse Events and Progression-free Survivals in PD-1/PD-L1 Inhibitor Monotherapy. In Vivo. 2024;38(6):2886-96.

14. Takahashi S, Bando H, Kinoshita I, Modi S, Tsurutani J, Bang YJ, Sato Y, Nakatani S, Lee C, Sugihara M, Okuda Y, Iwata H. Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studies. Jpn J Clin Oncol. 2024;54(4):434-43.

15. Suzuki N, Idogawa M, Emori M, Murase K, Arihara Y, Nakamura H, Usami M, Kubo T, Kinoshita I, Sugita S, Tokino T, Hasegawa T, Sakurai A, Takada K. LMNA::NTRK1 Fusion-positive Leiomyosarcoma: Discrepancy between DNA-based Comprehensive Genomic Profiling and RNA Sequencing. Intern Med. 2024;63(15):2215-9.

16. Sunami K, Naito Y, Saigusa Y, Amano T, Ennishi D, Imai M, Kage H, Kanai M, Kenmotsu H, Komine K, Koyama T, Maeda T, Morita S, Sakai D, Hirata M, Ito M, Kozuki T, Sakashita H, Horinouchi H, Okuma Y, Takashima A, Kubo T, Hironaka S, Segawa Y, Yakushijin Y, Bando H, Makiyama A, Suzuki T, Kinoshita I, Kohsaka S, Ohe Y, Ishioka C, Yamamoto K, Tsuchihara K, Yoshino T. A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence. JAMA Oncol. 2024;10(1):95-102.

17. Shimoi T, Sunami K, Tahara M, Nishiwaki S, Tanaka S, Baba E, Kanai M, Kinoshita I, Shirota H, Hayashi H, Nishida N, Kubo T, Mamesaya N, Ando Y, Okita N, Shibata T, Nakamura K, Yamamoto N. Dabrafenib and trametinib administration in patients with BRAF V600E/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial. EClinicalMedicine. 2024;69:102447.

18. Ohhara Y, Tomaru U, Kinoshita I, Hatanaka KC, Noguchi T, Hatanaka Y, Amano T, Matsuno Y, Dosaka-Akita H. Polymorphisms of the PD-L1 gene 3'-untranslated region are associated with the expression of PD-L1 in non-small cell lung cancer. Genes Chromosomes Cancer. 2024;63(1):e23216.

19. Ohhara Y, Kojima T, Honjo O, Yamada N, Sato T, Takahashi H, Takamura K, Takashina T, Sukoh N, Tanaka H, Kawai Y, Fujita Y, Yokoo K, Hommura F, Harada T, Honda R, Amano T, Dosaka-Akita H, Oizumi S, Kinoshita I. Non-small cell lung cancer with synchronous brain metastases: Identification of prognostic factors in a retrospective multicenter study (HOT 1701). Neurooncol Adv. 2024;6(1):vdae168.

20. Kikuchi Y, Shimada H, Hatanaka Y, Kinoshita I, Ikarashi D, Nakatsura T, Kitano S, Naito Y, Tanaka T, Yamashita K, Oshima Y, Nanami T. Clinical practice guidelines for molecular tumor markers, 2nd edition review part 1. Int J Clin Oncol. 2024;29(1):1-19.

2023年

1. Taniguchi O, Saito Y, Takekuma Y, Akita H, Kinoshita I, Shimizu Y, Shinagawa N, Sugawara M. Efficacy of antacids for cisplatin-induced gastrointestinal symptoms in the treatment of lung cancer. Int J Clin Pharmacol Ther. 2023;61(6):246-54.

2. Uchinami Y, Yasuda K, Kano S, Otsuka M, Hamada S, Suzuki T, Tsushima N, Takahashi S, Fujita Y, Miyazaki T, Higaki H, Taguchi J, Shimizu Y, Sakashita T, Homma A, Aoyama H. Treatment outcomes of radiotherapy with concurrent weekly cisplatin in older patients with locally advanced head and neck squamous cell carcinoma. Discov Oncol. 2023;14(1):226.

3. Saito Y, Tamaki S, Hirate D, Takada S, Takahashi K, Takekuma Y, Sakakibara-Konishi J, Shimizu Y, Kinoshita I, Sugawara M. Detection of factors related to treatment reduction in docetaxel and ramucirumab for non-small cell lung cancer treatment. Sci Rep. 2023;13(1):19457.

4. Saito Y, Kobayashi M, Tamaki S, Nakamura K, Hirate D, Takahashi K, Takekuma Y, Sakakibara-Konishi J, Shimizu Y, Kinoshita I, Sugawara M. Risk factor analysis for cisplatin-induced nephrotoxicity with the short hydration method in diabetic patients. Sci Rep. 2023;13(1):17126.

5. Takeuchi S, Hirata K, Magota K, Watanabe S, Moku R, Shiiya A, Taguchi J, Ariga S, Goda T, Ohhara Y, Noguchi T, Shimizu Y, Kinoshita I, Honma R, Tsuji Y, Homma A, Dosaka-Akita H. Early prediction of treatment outcome for lenvatinib using (18)F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study. EJNMMI Res. 2023;13(1):69.

6. Katabami M, Kinoshita I, Ariga S, Shimizu Y, Dosaka-Akita H. Crystalline silica-exposed human lung epithelial cells presented enhanced anchorage-independent growth with upregulated expression of BRD4 and EZH2 in autocrine and paracrine manners. PLoS One. 2023;18(5):e0285354.

7. Shiiya A, Noguchi T, Tomaru U, Ariga S, Takashima Y, Ohhara Y, Taguchi J, Takeuchi S, Shimizu Y, Kinoshita I, Koizumi T, Matsuno Y, Shinagawa N, Sakakibara-Konishi J, Dosaka-Akita H. EGFR inhibition in EGFR-mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment. Cancer Sci. 2023;114(4):1270-83.

8. Yamaguchi A, Saito Y, Narumi K, Furugen A, Takekuma Y, Shinagawa N, Shimizu Y, Dosaka-Akita H, Sugawara M, Kobayashi M. Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy. J Cancer Res Clin Oncol. 2023;149(4):1659-66.

9. Otsuka M, Yasuda K, Uchinami Y, Tsushima N, Suzuki T, Kano S, Suzuki R, Miyamoto N, Minatogawa H, Dekura Y, Mori T, Nishioka K, Taguchi J, Shimizu Y, Katoh N, Homma A, Aoyama H. Detailed analysis of failure patterns using deformable image registration in hypopharyngeal cancer patients treated with sequential boost intensity-modulated radiotherapy. J Med Imaging Radiat Oncol. 2023;67(1):98-110.

10. Iijima K, Takayama T, Shindo S, Moku R, Sawai K, Honma R, Hyakushima N, Akino T, Oyamada Y, Tsuji Y. Cancer of unknown primary eventually diagnosed as poorly differentiated prostate cancer: a case report. J Med Case Rep. 2023;17(1):376.

11. Ariga S. History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer. J Clin Med. 2023;12(10):3391.

12. Takeno N, Tarumi S, Abe M, Suzuki Y, Kinoshita I, Kato T. Lung adenocarcinoma with micropapillary and solid patterns: Recurrence rate and trends. Thorac Cancer. 2023;14(30):2987-92.

13. Hagio K, Kikuchi J, Takada K, Tanabe H, Sugiyama M, Ohhara Y, Amano T, Yuki S, Komatsu Y, Osawa T, Hatanaka KC, Hatanaka Y, Mitamura T, Yabe I, Matsuno Y, Manabe A, Sakurai A, Ishiguro A, Takahashi M, Yokouchi H, Naruse H, Mizukami Y, Dosaka-Akita H, Kinoshita I. Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers. Cancer Sci. 2023;114(8):3385-95.

2022年

1. Takahashi S, Oridate N, Tanaka K, Shimizu Y, Fujimoto Y, Matsumoto K, Yokota T, Yamazaki T, Takahashi M, Ueda T, Hanai N, Yamaguchi H, Hara H, Yoshizaki T, Yasumatsu R, Nakayama M, Shiga K, Fujii T, Mitsugi K, Takahashi K, Nohata N, Gumuscu B, Swaby RF, Tahara M. First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048. Int J Clin Oncol. 2022;27(12):1805-17.

2. Saito Y, Sakamoto T, Takekuma Y, Kobayashi M, Okamoto K, Shinagawa N, Shimizu Y, Kinoshita I, Sugawara M. Diabetes mellitus degenerates cisplatin-induced nephrotoxicity in short hydration method: a propensity score-matching analysis. Sci Rep. 2022;12(1):21819.

3. Saito Y, Takekuma Y, Takeshita T, Noguchi T, Takeuchi S, Shimizu Y, Kinoshita I, Dosaka-Akita H, Sugawara M. Risk Factor Analysis for the Occurrence of Severe Adverse Effects in Eribulin Treatment. Anticancer Res. 2022;42(7):3693-700.

4. Saito Y, Takekuma Y, Kobayashi M, Shinagawa N, Noguchi T, Takeuchi S, Shimizu Y, Kinoshita I, Dosaka-Akita H, Sugawara M. Suitability of Oral Rehydration Solution (ORS) for Use in the Cisplatin Short Hydration Method. Anticancer Res. 2022;42(6):3185-93.

5. Ohhara Y, Kinoshita I, Suzuki A, Imagawa M, Taguchi J, Noguchi T, Takeuchi S, Shimizu Y, Seki H, Suzuki J, Dosaka-Akita H. Expression of Karyopherin Alpha 2 and Karyopherin Beta 1 Correlate with Poor Prognosis in Gastric Cancer. Oncology. 2022;100(12):685-95.

6. Yasumatsu R, Shimizu Y, Hanai N, Kariya S, Yokota T, Fujii T, Tsukahara K, Ando M, Hanyu K, Ueda T, Hirakawa H, Takahashi S, Ono T, Sano D, Yamauchi M, Watanabe A, Omori K, Yamazaki T, Monden N, Kudo N, Arai M, Yonekura S, Asakage T, Nekado T, Yamada T, Homma A. Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study. Int J Clin Oncol. 2022;27(1):95-104.

7. Takada K, Kubo T, Kikuchi J, Yoshida M, Murota A, Arihara Y, Nakamura H, Nagashima H, Tanabe H, Sugita S, Tanaka Y, Miura A, Ohhara Y, Ishiguro A, Yokouchi H, Kawamoto Y, Mizukami Y, Ohnishi H, Kinoshita I, Sakurai A. Effect of comprehensive cancer genomic profiling on therapeutic strategies and clinical outcomes in patients with advanced biliary tract cancer: A prospective multicenter study. Front Oncol. 2022;12:988527.

8. Naito Y, Sunami K, Kage H, Komine K, Amano T, Imai M, Koyama T, Ennishi D, Kanai M, Kenmotsu H, Maeda T, Morita S, Sakai D, Watanabe K, Shirota H, Kinoshita I, Yoshioka M, Mamesaya N, Ito M, Kohsaka S, Saigusa Y, Yamamoto K, Hirata M, Tsuchihara K, Yoshino T. Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan. JAMA Netw Open. 2022;5(12):e2245081.

9. Minamoto A, Yamada T, Shimada S, Kinoshita I, Aoki Y, Oda K, Ueki A, Higashigawa S, Morikawa M, Sato Y, Hirasawa A, Ogawa M, Kondo T, Yoshioka M, Kanai M, Muto M, Kosugi S. Current status and issues related to secondary findings in the first public insurance covered tumor genomic profiling in Japan: multi-site questionnaire survey. J Hum Genet. 2022;67(10):557-63.

10. Chiba Y, Sudo K, Kojima Y, Okuma H, Kohsaka S, Machida R, Ichimura M, Anjo K, Kurishita K, Okita N, Nakamura K, Kinoshita I, Takahashi M, Matsubara J, Kusaba H, Yonemori K, Takahashi M. A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial. BMC Cancer. 2022;22(1):869.

2021年

1. Kariya S, Shimizu Y, Hanai N, Yasumatsu R, Yokota T, Fujii T, Tsukahara K, Yoshida M, Hanyu K, Ueda T, Hirakawa H, Takahashi S, Ono T, Sano D, Yamauchi M, Watanabe A, Omori K, Yamazaki T, Monden N, Kudo N, Arai M, Yonekura S, Asakage T, Fujiwara A, Yamada T, Homma A. Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting. Int J Clin Oncol. 2021;26(6):1049-56.

2. Hanai N, Shimizu Y, Kariya S, Yasumatsu R, Yokota T, Fujii T, Tsukahara K, Yoshida M, Hanyu K, Ueda T, Hirakawa H, Takahashi S, Ono T, Sano D, Yamauchi M, Watanabe A, Omori K, Yamazaki T, Monden N, Kudo N, Arai M, Sakurai D, Asakage T, Doi I, Yamada T, Homma A. Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study. Int J Clin Oncol. 2021;26(3):494-506.

3. Saito Y, Takekuma Y, Kobayashi M, Shinagawa N, Shimizu Y, Kinoshita I, Dosaka-Akita H, Iseki K, Sugawara M. Impact of histamine type-2 receptor antagonists on the anticancer efficacy of gefitinib in patients with non-small cell lung cancer. Eur J Clin Pharmacol. 2021;77(3):381-8.

4. Taguchi J, Shimizu Y, Ariga S, Goda T, Ohhara Y, Honma R, Noguchi T, Takeuchi S, Kinoshita I, Amano T, Mizumachi T, Kano S, Takahara M, Abe T, Homma A, Dosaka-Akita H. Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck. Int J Clin Oncol. 2021;26(1):51-8.

5. Hane Y, Tsuchikawa T, Takeuchi S, Tanaka K, Nakanishi Y, Asano T, Noji T, Kurashima Y, Ebihara Y, Murakami S, Nakamura T, Okamura K, Shichinohe T, Hirano S. Long-term survival after repetitive lymphadenectomy for nodal recurrence of pancreatic neuroendocrine neoplasms: a report of two cases. J Surg Case Rep. 2021;2021(10):rjab446.

6. Takahashi S, Karayama M, Takahashi M, Watanabe J, Minami H, Yamamoto N, Kinoshita I, Lin CC, Im YH, Achiwa I, Kamiyama E, Okuda Y, Lee C, Bang YJ. Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. Clin Cancer Res. 2021;27(21):5771-80.

7. Sunami K, Bando H, Yatabe Y, Naito Y, Takahashi H, Tsuchihara K, Toyooka S, Mimori K, Kohsaka S, Uetake H, Kinoshita I, Komine K, Takeda M, Hayashida T, Tamura K, Nishio K, Yamamoto N. Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA. Cancer Sci. 2021;112(9):3911-7.

8. Sugiyama M, Hirabayashi S, Ishi Y, Kikuchi J, Ishikura A, Motegi H, Ueda Y, Sawai S, Hara K, Terashita Y, Cho Y, Takakuwa E, Honda S, Yamaguchi S, Kinoshita I, Manabe A. Notable therapeutic response in a patient with systemic juvenile xanthogranuloma with KIF5B-ALK fusion. Pediatr Blood Cancer. 2021;68(11):e29227.

9. Naito Y, Aburatani H, Amano T, Baba E, Furukawa T, Hayashida T, Hiyama E, Ikeda S, Kanai M, Kato M, Kinoshita I, Kiyota N, Kohno T, Kohsaka S, Komine K, Matsumura I, Miura Y, Nakamura Y, Natsume A, Nishio K, Oda K, Oda N, Okita N, Oseto K, Sunami K, Takahashi H, Takeda M, Tashiro S, Toyooka S, Ueno H, Yachida S, Yoshino T, Tsuchihara K; Japanese Society of Medical Oncology; Japan Society of Clinical Oncology; Japanese Cancer Association. Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1). Int J Clin Oncol. 2021;26(2):233-83.

10. Kiuchi T, Tomaru U, Ishizu A, Imagawa M, Iwasaki S, Suzuki A, Otsuka N, Ohhara Y, Kinoshita I, Matsuno Y, Dosaka-Akita H, Kasahara M. Expression of the immunoproteasome subunit beta5i in non-small cell lung carcinomas. J Clin Pathol. 2021;74(5):300-6.

11. Kikuchi J, Ohhara Y, Takada K, Tanabe H, Hatanaka K, Amano T, Hatanaka KC, Hatanaka Y, Mitamura T, Kato M, Shibata Y, Yabe I, Endoh A, Komatsu Y, Matsuno Y, Sugiyama M, Manabe A, Sakurai A, Takahashi M, Naruse H, Torimoto Y, Dosaka-Akita H, Kinoshita I. Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan. Jpn J Clin Oncol. 2021;51(5):753-61.

12. Hagio K, Amano T, Hayashi H, Takeshita T, Oshino T, Kikuchi J, Ohhara Y, Yabe I, Kinoshita I, Nishihara H, Yamashita H. Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer. Sci Rep. 2021;11(1):8109.

2020年

1. Yen CJ, Kiyota N, Hanai N, Takahashi S, Yokota T, Iwae S, Shimizu Y, Hong RL, Goto M, Kang JH, Li WSK, Ferris RL, Gillison M, Endo T, Jayaprakash V, Tahara M. Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141). Head Neck. 2020;42(10):2852-62.

2. Takahashi K, Ishibashi E, Kubo T, Harada Y, Hayashi H, Kano M, Shimizu Y, Shirota H, Mori Y, Muto M, Ishioka C, Dosaka-Akita H, Matsubara H, Nishihara H, Sueoka-Aragane N, Toyooka S, Hirakawa A, Tateishi U, Miyake S, Ikeda S. A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial). Medicine. 2020;99(32):e21457.

3. Enokida T, Ogawa T, Homma A, Okami K, Minami S, Nakanome A, Shimizu Y, Maki D, Ueda Y, Fujisawa T, Motegi A, Ohkoshi A, Taguchi J, Ebisumoto K, Nomura S, Okano S, Tahara M. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck. Cancer Med. 2020;9(5):1671-82.

4. Kitagataya T, Suda G, Nagashima K, Katsurada T, Yamamoto K, Kimura M, Maehara O, Yamada R, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Komatsu Y, Hata H, Takeuchi S, Abe T, Sakakibara-Konishi J, Teshima T, Homma A, Sakamoto N. Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan. J Gastroenterol Hepatol. 2020;35(10):1782-8.

5. Hane Y, Tsuchikawa T, Tanaka K, Nakanishi Y, Asano T, Noji T, Kurashima Y, Ebihara Y, Murakami S, Nakamura T, Okamura K, Takeuchi S, Shichinohe T, Hirano S. Metachronous liver metastases after long-term follow-up of endoscopic resection for rectal neuroendocrine neoplasms: a report of three cases. Surg Case Rep. 2020;6(1):22.

6. Yatabe Y, Sunami K, Goto K, Nishio K, Aragane N, Ikeda S, Inoue A, Kinoshita I, Kimura H, Sakamoto T, Satouchi M, Shimizu J, Tsuta K, Toyooka S, Nishino K, Hatanaka Y, Matsumoto S, Mikubo M, Yokose T, Dosaka-Akita H. Multiplex gene-panel testing for lung cancer patients. Pathol Int. 2020;70(12):921-31.

7. Takashima Y, Kikuchi E, Kikuchi J, Suzuki M, Kikuchi H, Maeda M, Shoji T, Furuta M, Kinoshita I, Dosaka-Akita H, Sakakibara-Konishi J, Konno S. Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer. Int J Cancer. 2020;146(4):1114-24.

8. Shoji T, Kikuchi E, Kikuchi J, Takashima Y, Furuta M, Takahashi H, Tsuji K, Maeda M, Kinoshita I, Dosaka-Akita H, Sakakibara-Konishi J, Konno S. Evaluating the immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancer. Cancer Chemother Pharmacol. 2020;85(5):843-53.

9. Saito Y, Kobayashi M, Yamada T, Sakakibara-Konishi J, Shinagawa N, Kinoshita I, Dosaka-Akita H, Iseki K. Efficacy of additional dexamethasone administration for the attenuation of paclitaxel-associated acute pain syndrome. Support Care Cancer. 2020;28(1):221-7.

10. Hayashi H, Tanishima S, Fujii K, Mori R, Okada C, Yanagita E, Shibata Y, Matsuoka R, Amano T, Yamada T, Yabe I, Kinoshita I, Komatsu Y, Dosaka-Akita H, Nishihara H. Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system. Cancer Sci. 2020;111(10):3926-37.

11. Fukumoto SI, Oizumi S, Harada M, Sukoh N, Nakano K, Fuke S, Sakakibara-Konishi J, Takamura K, Ito K, Fujita Y, Nishigaki Y, Harada T, Akie K, Kinoshita I, Amano T, Isobe H, Dosaka-Akita H, Nishimura M, on behalf of the Hokkaido Lung Cancer Clinical Study Group. A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703). Cancer Chemother Pharmacol. 2020;86(1):117-27.